CDSCO panel recommends Biological E 14-valent paediatric vaccine against S pneumonia
New Delhi: Biological E Limited on Thursday announced that the Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) reviewed and approved the Phase 3 infants' clinical trial data and recommended for manufacture its 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) against S pneumonia infection, in single-dose and multi-dose presentations.
A press release from the city-based vaccine maker said the PCV14 can be administered to infants at six, 10 and 14 weeks of age. Streptococcus pneumoniae infection continues to be a leading cause of child mortality under 5 years of age in India and in developing countries.
Read also: Biological E to infuse over Rs 1800 crore to ramp up production of vaccines, injectables, RnD
With the PCV14 vaccine, BE hopes to contribute to the prevention of invasive pneumococcal disease and protect millions of lives globally.
The safety analysis of the vaccine revealed that all the adverse events were mild to moderate in their intensity and with no grade-3 & 4 events reported.
Read also: Eyestem raises Rs 51 crore in Series A round led by Biological E, Alkem, Natco and others
Founded and led by Dr. DVK Raju, Biological E. Limited commenced its operations in 1953. The company currently has four strategic business units Branded Formulations, Speciality Generic Injectables, Synthetic Biology and Vaccines and Biologics.
